Detalhe da pesquisa
1.
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.
Eur Respir J
; 54(4)2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31391223
2.
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
Clin Endocrinol (Oxf)
; 71(4): 549-57, 2009 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-19438906
3.
Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.
Eur J Endocrinol
; 161(4): 533-40, 2009 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-19654233